Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Journal article published in 2020 by
Wout Devlies 
,
Markus Eckstein,
Alessia Cimadamore ,
Gaëtan Devos ,
Lisa Moris,
Thomas Van den Broeck,
Rodolfo Montironi,
Steven Joniau ,
Frank Claessens ,
Thomas Gevaert
,
Markus Eckstein,
Alessia Cimadamore ,
Gaëtan Devos ,
Lisa Moris,
Thomas Van den Broeck,
Rodolfo Montironi,
Steven Joniau ,
Frank Claessens ,
Thomas Gevaert
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.